[
  {
    "ts": null,
    "headline": "NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects",
    "summary": "A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side effects. At Charing Cross Hospital in London, about 170 multiple sclerosis patients experienced complications, including relapses, mobility issues, fatigue, pain, and weight gain. Some cases were severe enough to require hospitalization. Also Read: Biogen Strengthens Pipeline With Stoke Therapeutic’s Dra",
    "url": "https://finnhub.io/api/news?id=378e1260615827cfc4d736e9f230f9e257e5ccbb065b2a2af43c15902e68981a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740418773,
      "headline": "NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects",
      "id": 133191258,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side effects. At Charing Cross Hospital in London, about 170 multiple sclerosis patients experienced complications, including relapses, mobility issues, fatigue, pain, and weight gain. Some cases were severe enough to require hospitalization. Also Read: Biogen Strengthens Pipeline With Stoke Therapeutic’s Dra",
      "url": "https://finnhub.io/api/news?id=378e1260615827cfc4d736e9f230f9e257e5ccbb065b2a2af43c15902e68981a"
    }
  },
  {
    "ts": null,
    "headline": "Biogen : to Participate in the TD Cowen 45th Annual Health Care Conference",
    "summary": "Cambridge, MA, - - Biogen Inc. announced today that Christopher A. Viehbacher, President and Chief Executive Officer, will participate in a fireside chat during the TD Cowen 45th Annual Health Care...",
    "url": "https://finnhub.io/api/news?id=1d0fd8c8b5dc7475dbcf06900281d80b3055f6042a4d103cbbc0ae2b9ec6af81",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740414067,
      "headline": "Biogen : to Participate in the TD Cowen 45th Annual Health Care Conference",
      "id": 132865852,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Cambridge, MA, - - Biogen Inc. announced today that Christopher A. Viehbacher, President and Chief Executive Officer, will participate in a fireside chat during the TD Cowen 45th Annual Health Care...",
      "url": "https://finnhub.io/api/news?id=1d0fd8c8b5dc7475dbcf06900281d80b3055f6042a4d103cbbc0ae2b9ec6af81"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Hires Top FDA Official Just Weeks After She Leaves Agency",
    "summary": "Pfizer Hires Top FDA Official Just Weeks After She Leaves Agency",
    "url": "https://finnhub.io/api/news?id=cdffe168c1ec41691900223c672589359d0772921c2def59f987acc0c838d6b7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740405840,
      "headline": "Pfizer Hires Top FDA Official Just Weeks After She Leaves Agency",
      "id": 134161433,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Pfizer Hires Top FDA Official Just Weeks After She Leaves Agency",
      "url": "https://finnhub.io/api/news?id=cdffe168c1ec41691900223c672589359d0772921c2def59f987acc0c838d6b7"
    }
  }
]